Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-Cell CLL/Lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus

Basic and Clinical Pharmacology and Toxicology

Volumn 105, Issue 2, 2009, Pages 113-119

  Hammonds, Michael D ^a   Shim, Seong S ^a,b  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; LITHIUM CARBONATE; OLANZAPINE; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DENTATE GYRUS; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; LITHIUM BLOOD LEVEL; MALE; MOLECULAR DYNAMICS; NERVE CELL PLASTICITY; NEUROPHARMACOLOGY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TREATMENT DURATION; UPREGULATION;

ANIMALS; BENZODIAZEPINES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DENTATE GYRUS; HIPPOCAMPUS; LITHIUM; LITHIUM CARBONATE; MALE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY;

EID: 68349088096     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00416.x     Document Type: Article

References (62)

1. Harrison PJ. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology 2004 174 : 151 62.
2. Harrison PJ. The neuropathology of primary mood disorder. Brain 2002 125 : 1428 49.
3. Manji HK, Moore GJ, Chen G. Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers. Br J Psychiatry 2001 178 : s107 19.
4. Chuang DM. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. An NY Acad Sci 2005 1053 : 195 204.
5. Chuang DM, Chen RW, Chalecka-Franaszek E, Ren M, Hashimoto R, Senatorov V et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002 4 : 129 36.
6. Manji HK, Lenox RH. Protein kinase C signaling in the brain: molecular transduction of mood stabilizers in manic depressive illness. Biol Psychiatry 1999 15 : 1328 51.
7. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000 75 : 1729 34.
8. Shim SS, Hammonds M, Ganocy SJ, Calabrese JR. Effects of lithium exposure on synaptic plasticity in the dentate gyrus of the hippocampus. Prog Neuropsychopharmacol Biol Psychiat 2007 31 : 343 7.
9. Son H, Yu IT, Hwang SJ, Kim JS, Lee SH, Lee YS et al. Lithium enhances long-term potentiation independently of hippocampal neurogenesis in the rat dentate gyrus. J Neurochem 2003 85 : 872 81.
10. Chuang DM. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 2004 16 : 83 90.
11. Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE Jr. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006 67 : 509 16.
12. Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disorder 2007 9 : 394 412.
13. Goldberg JF, Citrome L. Latest therapies for bipolar disorder. Looking beyond lithium. Postgrad Med 2005 117 : 25 6.
14. Goodnick PJ, Barrios CA. Use of olanzapine in non-psychotic psychiatric disorders. Expert Opin Pharmacother 2001 2 : 667 80.
15. Gama CS, Andreazza AC, Kunz M, Berk M, Belmonte-de-Abreu PS, Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 2007 420 : 45 8.
16. Kurosawa S, Hashimoto E, Ukai W, Toki S, Saito S, Saito T. Olanzapine potentiates neuronal survival and neural stem cell differentiation: regulation of endoplasmic reticulum stress response proteins. J Neural Transm 2007 114 : 1121 28.
17. Lieberman JA, Perkins DO, Jarskog LF. Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. CNS Spectr 2007 12 (3 Suppl 4 1 13.
18. Wakade C, Mahadi SP, Walley JL, Chiu FC. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 2002 69 : 72 9.
19. Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth Factors 2004 2 : 123 31.
20. McAllister AK, Katz LC, Lo DC. Neurotrophins and synaptic plasticity. Ann Rev Neurosci 1999 22 : 295 318.
21. Poo M-m. Neurotrohins as synaptic modulators. Nature Rev Neurosci 2001 2 : 24 32.
22. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998 281 : 1322 26.
23. Tsujimoto Y, Shimizu S. The voltage-dependent anion channel: an essential player in apoptosis. BioChemie 2002 84 : 187 93.
24. Finkbeiner S. CREB couples neurotrophin signals to survival messages. Neuron 2000 25 : 11 14.
25. Shaywitz AJ, Greenberg ME. CREB: A stimulus-induced transcription factor activated by a diverse array of extracellular signals. An Rev Biochem 1999 68 : 821 61.
26. Josslyn SA, Mortezavi M, Silva AJ. CREB: A cornerstone of memory consolidation? In : Stanton PK, Bramham C, Scharfman HE. (eds). Synaptic Plasticity and Transsynaptic Signaling. Springer Science, New York, NY, 2005 359 80.
27. Silva AJ, Kogon JH, Frankland PW. Creb and memory. An Rev Neurosci 1998 21 : 127 48.
28. Smith DF, Amdisen A. Central effects of lithium in rats: lithium levels, body weight and water intake. Acta Pharmacol Toxicol 1983 52 : 81 5.
29. Parikh V, Khan MM, Mahadik SP. Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. Neurosci Lett 2004 356 : 135 9.
30. Parikh V, Terry AV, Khan MM, Mahadik SP. Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine. Psychopharmacology 2004a 172 : 365 74.
31. Gould E, Tanapat P, Rydel T. Hastings N. Regulation of hippocampal neurogenesis in adulthood. Biol Psychiatry 2000 48 : 715 20.
32. Kandel ER, Kupferman I, Iversen S. Learning and Memory. In : Kandel ER, Schwartz JH, Jessell TM (eds). Principles of Neural Science. McGraw-Hill Companies, New York, NY, 2000 1227 46.
33. Einat H, Yuan P, Gould TD, Li J, Du JH, Zhang L et al. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 2003 23 : 7311 16.
34. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokin 1995 29 : 172 91.
35. Hammonds MD, Shim SS, Pingfu F, Calabrese JR. Effects of subchronic lithium treatment on levels of BDNF, Bcl-2 and phospho-CREB in the rat hippocampus. Basic Clin Pharmacol Toxicol 2007 100 : 356 9.
36. De Bruin VMS, Marinho MMF, De Sousa FCF, Viana GSB. Behavioral and neurochemical alterations after lithium-pilocarpine administration in young and adult rats: a comparative study. Pharmacol Biochem Behav 2000 65 : 547 51.
37. Moore GJ, Bebchuk JM, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds IB et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 2000 48 : 1 8.
38. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain gray matter. Lancet 2000a 356 : 1241 42.
39. Sassi RB, Nicoletti M, Brambilla P, Malinger AG, Frank E, Kupfer DJ et al. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett 2002 329 : 243 45.
40. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996 153 : 151 62.
41. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology 2001 158 : 100 6.
42. Manji HK, Chen G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol Psychiatry 2002 7 : S46 56.
43. Ozaki N, Chuang DM. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J Neurochem 1997 69 : 2336 44.
44. Angelucci F, Aloe L, Jimenez-Vasquez P, Mathe AA. Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression. Int J Neuropsychopharm 2003 6 : 225 31.
45. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH et al. The mood stabilizing agents lithium and valproate robustly increase the expression of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999 72 : 879 82.
46. Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res 2004 1010 : 81 6.
47. Luo C, Xu H, Li XM. Post-stress changes in BDNF and Bcl-2 immunoreactivities in hippocampal neurons: effect of chronic administration of olanzapine. Brain Res 2004 1025 : 194 202.
48. He J, Xu H, Yang Y, Zhang X, Li XM. Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of Bcl-2 decrease in rats. Brain Res 2004 1018 : 186 92.
49. Turalba AV, Leite-Morris KA, Kaplan GB. Antipsychotics regulate cyclic AMP-dependent protein kinase and phosphorylated cyclic AMP response element-binding protein in striatal and cortical brain regions in mice. Neurosci Lett 2004 357 : 53 7.
50. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003 71 : 127 31.
51. Angelucci F, Aloe L, Iannitelli A, Gruber, SH, Mathé AA. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur Neuropsychopharmacol 2005 15 : 311 7.
52. Pillai A, Terry AV Jr, Mahadik SP. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res 2006 82 : 95 106.
53. Fumagalli F, Molteni R, Roceri M, Bedogni F, Santero R, Fossati C et al. Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-d-aspartate receptor activity. J Neurosci Res 2003 72 : 622 28.
54. Lieberman DZ, Goodwin FK. Use of olanzapine in the treatment of bipolar I disorder. Expert Rev Neurother 2004 4 : 759 67.
55. Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schiz Res 2006 81 : 47 63.
56. Verkrellis K, McCarthy MJ, Watson A, Whitfiled J, Rubin LL, Ham J. Bax promotes neuronal cell death and is downregulated during the development of the nervous system. Development 1997 124 : 1239 49.
57. Terao T, Nakano H, Inoue Y, Okamoto T, Nakamura J, Iwata N. Lithium and dementia: A preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2007 30 : 1125 8.
58. Grinwood PD, Martin SJ, Morris RG. Synaptic plasticity and memory. In : Cowan WM, Sudhof TC, Stevens CF (eds). Synapses. The Johns Hopkins University Press, Baltimore, MA, 2001 519 70.
59. Morris RGM, Moser EI, Riedel DG, Martin SJ, Sandin J, Day M et al. Elements of a neurobiological theory of the hippocampus: the role of activity-dependent synaptic plasticity in memory. Philos Trans R Soc London Ser B 2003 358 : 773 86.
60. Nocjar C, Hammonds MD, Shim SS. Chronic lithium treatment magnifies learning in rats. Neuroscience 2007 74 : 774 88.
61. McGlashan TH. Is active psychosis neurotoxic? Schizophr Bull 2006 32 : 609 13.
62. Manji HK, Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001 35 : 5 49.